Treatment outcomes of ziv‐aflibercept for treatment‐naïve polypoidal choroidal vasculopathy

Chan, Errol W.; Eldeeb, Mohab; Govindhari, Vishal; Sarvaiya, Chintan; Banker, Alay; Mansour, Ahmad M.; Chhablani, Jay

doi:10.1111/aos.13533

Cited by 7 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 92 ] A subsequent study has evaluated the 9-month efficacy and safety of ziv-aflibercept in the treatment of PCV, where improvement in BCVA and decrease in CRT were comparable to studies using other anti-VEGF monotherapy. [ 93 ] Although the long-term efficacy of ziv-aflibercept is yet to be determined, its lower cost might make it a potential cost-effective treatment option in PCV.…”

Section: Management Of Pcvmentioning

confidence: 99%

Current management strategy of polypoidal choroidal vasculopathy

Lai

2018

Indian J Ophthalmol

View full text Add to dashboard Cite

Polypoidal choroidal vasculopathy (PCV) is a retinal disorder commonly found in Asians presenting as neovascular age-related macular degeneration and is characterized by serous macular detachment, serous or hemorrhagic pigment epithelial detachment, subretinal hemorrhage, and occasionally visible orange-red subretinal nodular lesions. PCV is diagnosed using indocyanine green angiography (ICGA), and the lesions appear as polypoidal aneurysmal vascular lesions with or without abnormal branching vascular network. Although ICGA remains the gold standard for the diagnosis of PCV, various imaging modalities have also facilitated the diagnosis and monitoring of PCV. Recent advances in imaging technology including the use of high resolution spectral domain optical coherence tomography (OCT) and OCT angiography have provided new insights on the pathogenesis of PCV, suggesting a link between PCV and pachychoroid spectrum of macular disorders. With the evolving understanding on the pathogenesis and clinical characteristics of PCV, different therapeutic options have been proposed. These include intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy, combination therapy with anti-VEGF and verteporfin photodynamic therapy, and thermal laser photocoagulation. In recent years, major multi-center randomized clinical trials such as EVEREST, EVEREST II, and PLANET studies have been conducted to compare the efficacy and safety of various treatment options for PCV. This review aims to summarize the results of recent literature, clinical trials and studies to provide an update on the management options of PCV. An overall management strategy for PCV will also be proposed.

show abstract

Section: Management Of Pcvmentioning

confidence: 99%

Current management strategy of polypoidal choroidal vasculopathy

Lai

2018

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Cependant, les préoccupations initiales concernant la cytotoxicité et l'innocuité à long terme des injections du Zaltrap® en intravitréen ont été en grande partie dissipées après qu'une série d'études n'aient pas permis d'identifier des effets indésirables oculaires et systémiques chez l'animal puis chez l'homme[7]. Plusieurs cas publiés ont en effet démontré que le Zaltrap® en intravitréen était sans danger et efficace pour le traitement de diverses maladies vasculaires choriorétiniennes à court et à long terme à la dose de 1,25 mg[8][9][10] et à court terme à la dose de 2 mg[11]. Des études prospectives randomisées sur le long terme et sur des cohortes plus importantes restent cependant nécessaires pour confirmer ces résultats.…”

unclassified

Dénominations et indications des anticorps face à la réglementation et aux pratiques des laboratoires pharmaceutiques

2019

View full text Add to dashboard Cite

Les dénominations et les indications des anticorps monoclonaux thérapeutiques doivent répondre aux réglementations en vigueur, mais s’accompagnent du développement de stratégies commerciales autour des noms commerciaux. Certaines de ces pratiques obéissent à des considérations territoriales ou juridiques, tandis que d’autres sont motivées par de réelles préoccupations médicales. Enfin, certaines ont un impact financier non négligeable pour la collectivité.

show abstract

“…reported that intravitreal injection of ziv-aflibercept was found to be effective against macular edema secondary to diabetes and retinal vein occlusion as well as AMD. [7] They have also reported improvement in BCVA and central macular thickness (CMT) with few side effects. Moreover, Chan et al .…”

mentioning

confidence: 99%

“…have reported that the outcomes of ziv-aflibercept in treating PCV were comparable to the outcomes of other major studies involving aflibercept, in terms of improved visual acuity and polyp regression. [7] Singh et al . also have reported better outcomes in treating PCV using ziv-aflibercept with improvements in visual acuity and reduction of pigment epithelial detachment as compared to using bevacizumab.…”

mentioning

confidence: 99%